At AAO 2026, Michael T. Yen, MD, explained how at-home subcutaneous elegrobart could ease treatment burden in thyroid eye disease.
Michael T. Yen, MD
Advertisement
Dr. Yen is assistant professor of ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston.
Articles by Michael T. Yen, MD
At AAO 2026, Michael T. Yen, MD, reviewed REVEAL-1 efficacy and hearing safety data for subcutaneous elegrobart in active TED.
Advertisement
Latest Updated Articles
Safety profile of elegrobart in the REVEAL-1 trialOctober 14th 2026
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Eyedaptic launches Eva, an agentic AI visual assistant for patients with retinal disease
2
FDA approves ranibizumab biosimilar Lucamzi for wet AMD
3
AAO 2026 recap: Christopher J. Rapuano, MD, on the meeting's themes
4
Eyes on October 2026: AAO and EURETINA highlights, a trio of FDA approvals, and optogenetics takes the spotlight
5